As of November 14, 2026, Centessa Pharmaceuticals plc has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from January 7, 2026 to June 24, 2026 (Form 8-K, June 24, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Centessa Pharmaceuticals plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-06-24
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-02-13
- · In / out: Reported · Person: not named in the filing · 8-K/A, 2026-01-07
Centessa Pharmaceuticals plc reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-01-07 to 2026-06-24. Every row below is cited to the filing it comes from, and this page adds each new change as Centessa Pharmaceuticals plc files it.
Also on the record for Centessa Pharmaceuticals plc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by INDEX VENTURES LIFE VI (JERSEY) L.P. | — | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Pentwater Capital Management LP | — | 5%+ stakes | Source |
| August 12, 2026 | Stake report, Schedule 13G/A, by Adage Capital Management, L.P. | — | 5%+ stakes | Source |
| August 4, 2026 | Stake report, Schedule 13G/A, by Medicxi Growth I LP | — | 5%+ stakes | Source |
| July 8, 2026 | Stake report, Schedule 13G/A, by FMR LLC | — | 5%+ stakes | Source |
| June 26, 2026 | Stake report, Schedule 13D/A, by FARALLON CAPITAL MANAGEMENT, L.L.C. | — | 5%+ stakes | Source |
| June 24, 2026 | Stake report, Schedule 13D, by FARALLON CAPITAL MANAGEMENT, L.L.C. | 6.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Pentwater Capital Management LP | 5.3% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Avoro Capital Advisors LLC | 7.39% of the class | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13G/A, by Adage Capital Management, L.P. | 5.77% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 7.5% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Avoro Capital Advisors LLC | 9.97% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Centessa Pharmaceuticals plc now and the warning signs.
Free to see. No signup.
Keep reading
More on Centessa Pharmaceuticals plc and the records around it.
Centessa Pharmaceuticals plc elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
- FARALLON CAPITAL MANAGEMENT, L.L.C. also filed stake reports on 19 other companies: Avalo Therapeutics, Inc. (Nov 2026), BridgeBio Pharma, Inc. (Nov 2026), Crinetics Pharmaceuticals, Inc. (Nov 2026)
- Pentwater Capital Management LP also filed stake reports on 20 other companies: AMC Entertainment Holdings, Inc. (Aug 2026), Caesars Entertainment, Inc. (Aug 2026), Core Scientific, Inc. (Aug 2026)
Watch Centessa Pharmaceuticals plc
Get an email when Centessa Pharmaceuticals plc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Centessa Pharmaceuticals plc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Centessa Pharmaceuticals plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Centessa Pharmaceuticals plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 20 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-24 | Reported | not named in the filing | 8-K, 2026-06-24 | ||
| 2026-02-13 | Reported | not named in the filing | 8-K, 2026-02-13 | ||
| 2026-01-07 | Reported | not named in the filing | 8-K/A, 2026-01-07 |
New leaders reset buying decisions — get the Full Report on Centessa Pharmaceuticals plc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Centessa Pharmaceuticals plc, with the record behind each one.
Find candidates like senior executive at Centessa Pharmaceuticals plcEvery change, in the filing's words
Reported
(Chief Executive Officer and Director), John Crowley, Stephen Kanes, M.D., Ph.D., and Raphael Deferiere ceased to serve in their capacities as executive officers of Centessa.
- Additionally, in connection with the Acquisition and as of the Effective Time, each of Francesco De Rubertis, Mario Alberto Accardi, Arjun Goyal, Mary Lynne Hedley, Mathias Hukkelhoven, Samarth Kulkarni, Carol Stuckley and Brett Zbar ceased serving as a member of the board of directors of Centessa and each committee thereof on which such director served.
- As of the Effective Time, Christopher Stokes and Kristina Mignon Wright were appointed as directors of the Company.
Reported
Pursuant to the Advisory Agreement, Dr. Saha has agreed to provide certain advisory services to the Company for an initial six-month period, automatically continuing thereafter unless terminated by either party, for an hourly advisory fee of $376.00, plus reimbursement of business expenses.
- As previously disclosed, effective January 1, 2026, Saurabh Saha, M.D., Ph.D., stepped down from his position as Chief Executive Officer and a member of the Board of Directors of Centessa Pharmaceuticals plc (the "Company" or "Centessa").
- In connection with his appointment as advisor to the CEO, on February 9, 2026, the Company entered into an Advisory Agreement (the "Advisory Agreement") and a separation agreement and general release (the "Separation Agreement") with Dr. Saha.
- These extended benefits are provided in lieu of any other severance payments or noncompetition consideration under prior agreements, and the Separation Agreement, which includes a general release of claims, becomes effective upon expiration of a seven-business-day revocation period following execution.
Reported
In connection with this appointment, on January 5, 2026, the Company and Dr. Accardi entered into an Employment Agreement (the "Employment Agreement"), effective as of January 1, 2026.
- Pursuant to the Employment Agreement, Dr. Accardi's base salary is $600,000 and he is eligible to earn a target annual bonus of fifty percent (50%) of his base salary.
- The Employment Agreement provides that if we terminate Dr. Accardi's employment outside of the one year period following a sale event (as defined in the Centessa Pharmaceuticals plc 2021 Stock Option and Incentive Plan, or the 2021 Plan) without cause, or Dr. Accardi resigns for good reason, Dr. Accardi will receive 12 months' salary continuation.
- The Employment Agreement provides that if Dr. Accardi's employment is terminated by us other than for cause, or by Dr. Accardi for good reason within the one year period following a sale event, Dr. Accardi will receive a lump sum payment equal to the sum of (A) 18 months of his then-current base salary and (B) 150% of his target bonus for the year of termination.
- In addition, the Employment Agreement provides that if any payments or benefits received by Dr. Accardi or otherwise would constitute "parachute payments" within the meaning of Section 280G of the Code and be subject to excise taxes imposed by Section 4999 of the Code, such amount will either be delivered in full or reduced so as not to be subject to excise taxation, whichever amount is higher.
Tools for this story
Each opens in a new tab, filled in for Centessa Pharmaceuticals plc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
